Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…
Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study
No data exist for prescribing hydroxychloroquine for post-exposure prophylaxis, and we should not prescribe it for this indication.
Enemy at the Gates: The Emerging Threat of COVID-19
On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…
Axial Spondyloarthritis & Exercise: Should axSpA Patients Exercise?
Two experts weigh in on whether & how axial spondyloarthritis patients should exercise…
New Options Emerge for Treating Macrophage Activation Syndrome
ATLANTA—Macrophage activation syndrome (MAS), a subset of hemophagocytic lymphohistiocytosis (HLH) disease, can be a fatal result of rheumatic disease. But there’s good news: New therapeutic options for refractory MAS targeting individual cytokines are emerging. At the 2019 ACR/ARP Annual Meeting, possible therapeutic options were presented during a pediatric-focused clinical and translational research track, Therapeutic Approaches…
Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts
ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…
New Research Identifies Possible Preclinical Rheumatoid Arthritis Biomarkers
ATLANTA—A key goal for rheumatology researchers and clinicians is to predict through specific biomarkers if someone will, at some point in their future, develop rheumatoid arthritis (RA). If so, the disease could be prevented or stopped before the inflammation and ravaging begins, explained researchers during a Basic Science lecture at the 2019 ACR/ARP Annual Meeting…
Statins Linked to Reduced Likelihood of Joint Replacement
NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show. “Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1 Statins have anti-inflammatory effects, and…
Strong Support for Treat-to-Target Strategy in RA Patients
NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…
Don’t Forget the Host: COVID-19 Cytokine Storm
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 334
- Next Page »